BD PharmingenTM PE Rat Anti-Human IL-6

Description

Expression of IL-6 by stimulated CD14+ human monocytes. Human PBMC were stimulated for 6 hours with LPS 100 ng/ml final concentration in the presence of GolgiStop 2 muM final concentration; Cat. No. 554724 . The PBMC were harvested, stained with FITC-mouse anti-human CD14 monoclonal antibody FITC-M5E2, Cat. No. 555397 , fixed, permeabilized, and subsequently stained with 20 mul of PE-rat anti-human IL-6 antibody PE-MQ2-6A3, Cat. No. 559331 , by following the Usage section below and the BD Pharmingen staining protocol left panel . The data reflect gating on monocytes, based on forward and side scatter. To demonstrate specificity of staining, the binding by PE-MQ2-6A3 was blocked by each of the following: 1 preincubation of the conjugated antibody with recombinant human IL-6 0.5 mug, Cat. No. 550071; middle panel and by 2 preincubation of the fixed/permeabilized cells with unlabeled MQ2-6A3 antibody 2.5 mug; Cat. No. 559068; right panel prior to staining with the PE-MQ2-6A3. The quadrant markers for the bivariate dot plots were set based on the autofluorescence controls and verified using the recombinant cytokine blocking and unlabeled antibody blocking specificity controls. Expression of IL-6 by stimulated CD14+ human monocytes. Human PBMC were stimulated for 6 hours with LPS 100 ng/ml final concentration in the presence of GolgiStop 2 muM final concentration; Cat. No. 554724 . The PBMC were harvested, stained with FITC-mouse anti-human CD14 monoclonal antibody FITC-M5E2, Cat. No. 555397 , fixed, permeabilized, and subsequently stained with 20 mul of PE-rat anti-human IL-6 antibody PE-MQ2-6A3, Cat. No. 559331 , by following the Usage section below and the BD Pharmingen staining protocol left panel . The data reflect gating on monocytes, based on forward and side scatter. To demonstrate specificity of staining, the binding by PE-MQ2-6A3 was blocked by each of the following: 1 preincubation of the conjugated antibody with recombinant human IL-6 0.5 mug, Cat. No. 550071; middle panel and by 2 preincubation of the fixed/permeabilized cells with unlabeled MQ2-6A3 antibody 2.5 mug; Cat. No. 559068; right panel prior to staining with the PE-MQ2-6A3. The quadrant markers for the bivariate dot plots were set based on the autofluorescence controls and verified using the recombinant cytokine blocking and unlabeled antibody blocking specificity controls. Expression of IL-6 by stimulated CD14+ human monocytes. Human PBMC were stimulated for 6 hours with LPS 100 ng/ml final concentration in the presence of GolgiStop 2 muM final concentration; Cat. No. 554724 . The PBMC were harvested, stained with FITC-mouse anti-human CD14 monoclonal antibody FITC-M5E2, Cat. No. 555397 , fixed, permeabilized, and subsequently stained with 20 mul of PE-rat anti-human IL-6 antibody PE-MQ2-6A3, Cat. No. 559331 , by following the Usage section below and the BD Pharmingen staining protocol left panel . The data reflect gating on monocytes, based on forward and side scatter. To demonstrate specificity of staining, the binding by PE-MQ2-6A3 was blocked by each of the following: 1 preincubation of the conjugated antibody with recombinant human IL-6 0.5 mug, Cat. No. 550071; middle panel and by 2 preincubation of the fixed/permeabilized cells with unlabeled MQ2-6A3 antibody 2.5 mug; Cat. No. 559068; right panel prior to staining with the PE-MQ2-6A3. The quadrant markers for the bivariate dot plots were set based on the autofluorescence controls and verified using the recombinant cytokine blocking and unlabeled antibody blocking specificity controls. Show More Expression of IL-6 by stimulated CD14+ human monocytes. Human PBMC were stimulated for 6 hours with LPS 100 ng/ml final concentration in the presence of GolgiStop 2 muM final concentration; Cat. No. 554724 . The PBMC were harvested, stained with FITC-mouse anti-human CD14 monoclonal antibody FITC-M5E2, Cat. No. 555397 , fixed, permeabilized, and subsequently stained with 20 mul of PE-rat anti-human IL-6 antibody PE-MQ2-6A3, Cat. No. 559331 , by following the Usage section below and the BD Pharmingen staining protocol left panel . The data reflect gating on monocytes, based on forward and side scatter. To demonstrate specificity of staining, the binding by PE-MQ2-6A3 was blocked by each of the following: 1 preincubation of the conjugated antibody with recombinant human IL-6 0.5 mug, Cat. No. 550071; middle panel and by 2 preincubation of the fixed/permeabilized cells with unlabeled MQ2-6A3 antibody 2.5 mug; Cat. No. 559068; right panel prior to staining with the PE-MQ2-6A3. The quadrant markers for the bivariate dot plots were set based on the autofluorescence controls and verified using the recombinant cytokine blocking and unlabeled antibody blocking specificity controls. Show More Expression of IL-6 by stimulated CD14+ human monocytes. Human PBMC were stimulated for 6 hours with LPS 100 ng/ml final concentration in the presence of GolgiStop 2 muM final concentration; Cat. No. 554724 . The PBMC were harvested, stained with FITC-mouse anti-human CD14 monoclonal antibody FITC-M5E2, Cat. No. 555397 , fixed, permeabilized, and subsequently stained with 20 mul of PE-rat anti-human IL-6 antibody PE-MQ2-6A3, Cat. No. 559331 , by following the Usage section below and the BD Pharmingen staining protocol left panel . The data reflect gating on monocytes, based on forward and side scatter. To demonstrate specificity of staining, the binding by PE-MQ2-6A3 was blocked by each of the following: 1 preincubation of the conjugated antibody with recombinant human IL-6 0.5 mug, Cat. No. 550071; middle panel and by 2 preincubation of the fixed/permeabilized cells with unlabeled MQ2-6A3 antibody 2.5 mug; Cat. No. 559068; right panel prior to staining with the PE-MQ2-6A3. The quadrant markers for the bivariate dot plots were set based on the autofluorescence controls and verified using the recombinant cytokine blocking and unlabeled antibody blocking specificity controls. Expression of IL-6 by stimulated CD14+ human monocytes. Human PBMC were stimulated for 6 hours with LPS 100 ng/ml final concentration in the presence of GolgiStop 2 muM final concentration; Cat. No. 554724 . The PBMC were harvested, stained with FITC-mouse anti-human CD14 monoclonal antibody FITC-M5E2, Cat. No. 555397 , fixed, permeabilized, and subsequently stained with 20 mul of PE-rat anti-human IL-6 antibody PE-MQ2-6A3, Cat. No. 559331 , by following the Usage section below and the BD Pharmingen staining protocol left panel . The data reflect gating on monocytes, based on forward and side scatter. To demonstrate specificity of staining, the binding by PE-MQ2-6A3 was blocked by each of the following: 1 preincubation of the conjugated antibody with recombinant human IL-6 0.5 mug, Cat. No. 550071; middle panel and by 2 preincubation of the fixed/permeabilized cells with unlabeled MQ2-6A3 antibody 2.5 mug; Cat. No. 559068; right panel prior to staining with the PE-MQ2-6A3. The quadrant markers for the bivariate dot plots were set based on the autofluorescence controls and verified using the recombinant cytokine blocking and unlabeled antibody blocking specificity controls.